Fig. 2

Pulrodemstat suppresses HNSCC progress. (A, B) The IC₅₀ of Pulrodemstat in each HNSCC cell lines were determined by CCK-8 assay. (C) The IC₅₀ across HNSCC cell lines were analyzed by Genomics of Drug Sensitivity in Cancer database. (D) The IC₅₀ of 5-Fu in each HNSCC cell lines were determined by CCK-8 assay. (E) The anti-tumor efficacy of Pulrodemstat in HNSCC cell lines were evaluated by colony formation assay. (F) Cal-27 cells were infected with indicated lentiviral constructs, followed by IB analysis as indicated. (G) Clonogenic assay in KDM1A-depleted Cal-27 cells. (H, I) Cal-27 cells stably expressing control or KDM1A shRNA were treated with Pulrodemstat and then subjected to IB (H) and clonogenic assay (I) as indicated. (J) The anti-metastasis capacity of Pulrodemstat in HNSCC cell liens were determined by transwell assay. Data in (J) was displayed as mean ± SD. Statistical significance was determined using Student’s t-test. ***P < 0.001